Novel TRPV1 Agonist Prodrugs for Pain
Novel TRPV1 Agonist Prodrugs for Pain
The Problem
The Problem
Treating pain systemically with opioids provides relief but dramatically increases costs and morbidity
Treating pain at its source with local anesthetic is effective, but limited by its short duration of action
Treating pain with regional blocks is highly effective, but duration is less than 24 hours and relief is accompanied by muscle weakness and sensory numbness
Pain is the most feared symptom with cancer (Jain 2015)
Overall pain prevalence is 33% (more than 75% with advanced disease) (Paice 2011)
Severe pain prevalence is 5% (increases with advanced disease) and predicts near-term hospitalizations (Wagner-Johnston 2010)
Opioids, while the mainstay of treatment, are limited by side effects
Eventually, conservative treatments fail and require invasive approaches which are costly
NSAIDS only effective for mild-to-moderate and have significant safety issues (GI, Renal, CV)
Opioids provide limited, short-term relief but dramatically increase costs and morbidity
Intra-articular (IA) steroids are somewhat effective yet limited due to short duration of action
IA hyaluronic acid has limited differentiation from placebo in controlled clinical studies
Goal
Goal
Attributes of our prodrugs
Attributes of our prodrugs
Reduced opioid consumption & opioid-related adverse events
Targets pain at source with limited systemic exposure
Single injection simplifies ongoing care
Continuous and durable relief
Extended pain relief without numbness or weakness